ArticleFrontiers in medicine2025
The association of polypharmacy with intrinsic capacity: an analysis of the WHO ICOPE pilot data from Lianyungang, China.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: As a core indicator of healthy aging, intrinsic capacity (IC) may be adversely impacted by polypharmacy. Leveraging data from the WHO Integrated Care for Older People (ICOPE) pilot in China, this study examines the association between polypharmacy and IC decline in older adults, aiming to provide evidence-based insights for optimizing geriatric pharmacotherapy. Methods: A cross-sectional analysis was conducted using data from community-dwelling and institutionalized adults aged ≥60 years enrolled at the Lianyungang (LYG) pilot site of the WHO ICOPE China program. Medication histories, demographic characteristics, lifestyle factors, and chronic disease profiles were collected via structured questionnaires. The WHO ICOPE screening tool was employed to assess five IC domains: cognition, mobility, sensory function, nutrition, and psychology. Polypharmacy was defined as concurrent use of ≥5 medications. Multivariable logistic regression models evaluated the polypharmacy-IC decline association, with stratification analyses assessing subgroup heterogeneity. Results: The study enrolled 467 participants, comprising a polypharmacy cohort (≥5 medications, Conclusion: An increase in the number of medications used by older adults may be positively associated with a decline in intrinsic capacity (IC). The prevalence of IC decline is significantly higher among individuals taking ≥5 medications compared to those using fewer medications. These findings suggest that polypharmacy is associated with IC decline and could serve as a potential indicator for IC decline. Prospective studies are needed to validate the causal relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.